REVIEW ARTICLE

“Mixed connective tissue disease”: a condition in search of an identity

Marta R. Alves1 · David A. Isenberg2

Received: 26 July 2019 / Accepted: 10 January 2020 © The Author(s) 2020

Abstract
Mixed connective tissue disease was first described as a new autoimmune rheumatic disease in 1972 based on the claim of a distinct clinical picture associated with anti-RNP antibody positivity. Subsequently, this new entity has divided opinions in the rheumatology community. We have reviewed recent cohort studies with more than 100 patients, comparing the clinical and immunological features, treatment, prognosis and evolution to well-defined autoimmune rheumatic diseases. We also reviewed clinical features of undifferentiated autoimmune rheumatic diseases based on the most recent studies. After gathering and reviewing these data, we discuss whether the designation “mixed connective tissue disease” should be maintained.

Keywords Mixed connective tissue disease · Anti-U1snRNP · Undifferentiated autoimmune rheumatic disease · Review · Clinical features · Immunologic features · Genetic features · Disease evolution

Introduction: a historical perspective

In 1972, Sharp et al. [1] described what was claimed to be a new rheumatological disease. Mixed connective tissue disease (“MCTD”) was reported to be an association of Raynaud’s phenomena, swollen fingers, oesophageal dysfunction, arthralgias, some with non-deforming arthritis, and absent pulmonary and renal disease, in 25 patients with high titres of anti-RNP antibody. This new syndrome consisted of overlapping features between scleroderma, systemic lupus erythematosus, polymyositis/dermatomyositis, with a favourable prognosis, and a low corticosteroid requirement. However, in 1980, Nimelstein et al. [2] reviewed these 25 patients and observed that 8 patients had died, 2 caused by rheumatologic/immunosuppressive-related conditions, and 3 patients could not be found. Most of the remaining 14 patients had evolved into well-defined autoimmune rheumatic diseases (ARD) or an overlap between two ARD. Treatment of these patients was heterogeneous, some requiring high levels of immunosuppression. Levels of anti-RNP antibodies had not in fact been high in all patients when first tested, and these levels did not correlate with disease severity. Several key features of the so-called MCTD were thus challenged casting doubt on the idea that “MCTD” was a distinct disease. Despite the claims made in the initial study, anti-RNP antibodies, even in high titre, lack specificity, the “MCTD” patients often evolve to other well-defined ARD and the idea that low-dose corticosteroid only was required was also challenged [3–9].

Many studies have explored the subject, but no really large-scale prospective studies have been undertaken, and the results of later studies have been just as contradictory [7–9].

Since it was first described, the clinical picture of “MCTD” has changed. Four different classification and diagnostic criteria have been developed (Sharp [10], Alarcon-Segovia [11], Kasukawa [12] and Kahn [13]) and compared in several studies. Which is the most sensitive and/or specific remains controversial [7–9].

Invariably, the discovery of blood test abnormalities, notably antibodies linked to an ARD, has followed its clinical description by many years. Thus, rheumatoid factor was described in the mid-twentieth century, whereas clinical descriptions of rheumatoid arthritis go back to the nineteenth century [14, 15]. Although agreeing that the “MCTD” discovery pathway was unusual and that unanswered questions remain, part of the rheumatological community still considers it a distinct disease [16–19]. This is due to an apparently
similar clinical picture in some anti-RNP-positive patients with overlapping features of ARD, a tendency to the insidious development of PAH (pulmonary arterial hypertension) and ILD (interstitial lung disease), and relatively uncommon renal or neurological involvement. A genetic association between HLA haplotype and anti-U1RNP antibodies was discovered, which some have interpreted as supporting the concept of MCTD [20–22]. However, other studies demonstrated that this linkage did not correlate with clinical disease expression, merely with antibody production [23, 24].

Data review

We have reviewed cohort studies with a significant number of patients (n > 100) and a follow-up period time of more than 5 years in an attempt to draw more tangible conclusions. Four studies were identified and compared. Studies with more than 100 patients are uncommon, though a study that analyses anti-RNP positive patients, with 50 MCTD patients, was also included. Cohort studies of Gunnarson et al. were not reviewed as they only address pulmonary disease in “MCTD”.

Cappelli et al. [25] identified 161 patients in 15 tertiary Italian centres. Patients included had “MCTD” diagnosed according to expert opinion and upon chart review were classified in accordance with the three main set of criteria (Kasukawa, Alarcón-Segovia and Sharp). Sixteen patients (9.9%) did not fulfil any diagnostic criteria after chart review. Every patient was subsequently evaluated with a mean disease duration of 7.9 ± 5.9 years (range 1–31 years). Patients that fulfilled diagnostic criteria for a well-established ARD at initial diagnosis were excluded. Notably, patients fulfilling criteria for “MCTD” and another ARD at study end (2008) were considered to have “MCTD”. Therefore, overlap and evolution to other ARDs were only considered to have occurred in patients no longer satisfying any “MCTD” criteria. In 22 patients (14%), no anti-RNP data were provided.

In the Reiseter et al. [26] cohort study, 147 patients were identified from the Norwegian nationwide “MCTD” database, and 118 were studied (13 patients were lost and 16 deceased before reevaluation). Inclusion criteria were age above 18 years, fulfilment of at least one of the three sets of criteria for “MCTD” (modified Sharp’s criteria, Alarcón-Segovia, Kasukawa) and exclusion of another ARD. Patients submitted to a protocol evaluation when the database was created (t1) and reevaluated for the study (t2). At t1, the mean disease duration was 10(± 8), and at t2, it was 17 (± 9) years. More than 90% of the 118 patients had disease duration > 8 years and were observed for > 5 years. Disease conversion was defined as change of antibody profile together with concordant clinical features of another ARD. In those patients in whom more than one specific autoantibody was identified, the dominant antibody specificity was determined together with the clinical features. It is not clear whether “MCTD” classified patients also fulfilled criteria for other ARD. Remission was considered and was evaluated using a combination of SLE and SSc validated activity criteria, though neither is validated for use in “MCTD”. Remission was defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) equal to zero and a European Scleroderma Trials and Research group score (EUSTAR) inferior to 2.5. The main goal of this study was to compare the characteristics at t1 of “MCTD” stable patients and disease converters.

Hajas et al. [27] recruited 280 patients followed at the Division of Clinical Immunology, University of Debrecen—Hungary, between 1979 and 2011. Mean follow-up time was 13.1 (± 7.5) years, and the Alarcón-Segovia criteria set was used for inclusion. It is not clear whether patients fulfilling other ARD criteria were excluded, nor which criteria were used to evaluate disease conversion. Disease activity was assessed using the Systemic Lupus Activity Measure index (SLAM), which is not validated for use in “MCTD”.

Ungprasert et al. [4] used the resources of the Rochester Epidemiology project to study the anti-U1RNP positive antibody Olmsted County, Minnesota, population. Between 1985 and 2014, 264 patients were identified. Inclusion criteria were age above 18 years and a positive anti-RNP antibody test. “MCTD” diagnosis was appraised using and comparing all four known criteria, without fulfilling other ARD criteria. Fifty patients fulfilled at least one of the “MCTD” criteria. Disease duration was characterized using median and interquartile range: 10 years (4.9; 14.3). The criteria used to evaluate disease conversion were not explained. Disease activity was not assessed.

Szodoray et al. [28] evaluated 201 patients from a single centre. Fulfilment of Alarcón-Segovia criteria was required for individuals in the study, and the mean follow-up time was 12.5(± 7.2) years. Although this was a longitudinal study, it is not clear whether clinical features and antibody profile described were at diagnosis or after follow-up. Patients were divided into three pathologic groups, with statistically significant different incidence of organ damage. Evolution to other ARD was not considered although Sjögren’s syndrome was described in 36.8% of patients. Treatment was not evaluated. Owing to the lack of clarity about the clinical data timing and the absence of evaluation of evolution to other ARDs, this study is not further discussed in this review.

Frandsen et al. [29] evaluated 151 patients with an anti-RNP positive antibody. In this study, anti-RNP antibody testing was undertaken by passive hemagglutination, which differs from all other studies which used ELISA. Furthermore, the “MCTD” diagnostic criteria used was that proposed by Rasmussen et al. and differs from all the other studies. Thus, we have not considered this study either in our analysis.
Clinical features

Table 1 summarizes and shows comparison of the clinical features described at diagnosis and the cumulative frequency after follow-up time in each study. Mean follow-up time is provided at each evaluation.

Comparing the most striking features of patients with “MCTD”, at diagnosis and cumulative frequency after around 10 years of follow-up, it is noticeable that they often differ substantially across the various studies. Puffy hands vary between 53 and 72% at presentation and 46% and 92% after follow-up. Raynaud’s phenomenon was present in between 50.3 and 93.2% at presentation and 57.5% to 99% after follow-up. Arthritis at presentation occurred between 65.3 and 86%, 49.7 and 89.6% after follow-up. Oesophageal hypomobility or dilation occurred in 34.8% to 38.9% at presentation and 45.3 to 49.6% during follow-up. Evolution to ILD and/or PHA is reported in some, but not all, studies. Some believe it to be a characteristic of patients with “MCTD” [30–32], but clearly in Table 1, after 10 years follow-up, this evolution is also not homogenous. PHA was only evaluated in two studies and occurred in between 6.9 and 17.8% of patients. ILD is addressed in 4 of the 5 studies and occurred in 27.8% to 47%.

Immunologic and genetic features

It is generally assumed that a positive anti-U1RNP antibody is necessary for a diagnosis of “MCTD” to be made. However, it is not exclusive to this condition. In our own group of Systemic Lupus Erythematosus (SLE) patients, anti-RNP antibodies were present in 35% [33]. Ungprasert

| Clinical features | Cappelli et al. (25) | Reiseter et al. (26). | Hajas et al. (27) | Ungprasert, et al. (4) |
|-------------------|---------------------|----------------------|-------------------|------------------------|
| n                 | At diagnoses 2008   | r1 (118 (134–16 deceased)) | At diagnoses 2011 | At diagnoses 264 (50) |
| Male gender       | 9%                  | 24%                  | 7.5%              | 16%                    |
| Age, years, mean (SD) | 44 (14)         | 53.1 (12.6)          | 48.1 (15.7)       |
| Follow-up time, years, mean (SD) | 7.9 (5.9) | 10 (8)               | 17 (9)            | 8.3 (3.4; 14.1) |
| Raynaud’s phenomenon | 93.2%             | 85.1%                | 99%               | 50.3%                  |
| Arthritis         | 73.9%c             | 49.7%                | 78%               | 65.3%                  |
| Puffy hands       | 72.7%              | 46.0%                | 92%               | 53.6%                  |
| Sclerodactyly     | 29.2%              | 43.0%                | 28%               | 35.3%                  |
| Hypomotility or dilatation of oesophagus | 34.8%             | 45.3%                | 38.9%              | 49.6%                  |
| Interstitial lung disease | 28.6%         | 44.1%                | 34%               | 0.7%                   |
| Pulmonary arterial hypertension | 0.0%             |                     |                   | 17.8%                  |
| Pleuritis         | 21.7%              | 18.6%                | 12%               | 13.9%                  |
| Pericarditis      | 9%                  |                     |                   | 9.0%                   |
| Facial erythema   | 19.9%              | 16.8%                | 44%               | 32.9%                  |
| Lymphadenopathy   | 18.0%              | 13.7%                |                   | 4%                     |
| Neurological involvement | 5.6%             | 11.2%                | 12.5%              | 20.0%                  |
| Myositis          | 27.9%f             | 19.2%                | 30%               | 13.5%                  |
| Renal involvement (nephritis) | 6.8%           | 9.9%                 | 0.0%               | 3.9%                   |
| Anti/phospholipid syndrome | NR             | NR                   | NR                | 3.9%                   |
| Cardiovascular involvement | NR             | NR                   | NR                | 7.5%                   |
| Cancer            | NR                  | NR                   | NR                | 0.0%                   |
| Leukopenia        | 24.8%              | 26.7%                | 31%               | 44%                    |
| Thrombocytopenia  | 14%                 | 6.7%                 | 22.5%             | 0%                     |

NR not reported

*a264 anti-RNP-positive patients studied, 50 where diagnosed with MCTD
bInterquartile range
cArthralgia was also considered
dErosive and non-erosive arthritis
eConsidered also photosensitivity, telangiectasia and hyper-pigmentation
fOnly elevated CK was considered
et al. studied 264 anti-RNP-positive patients, and a majority had other ARD, and only 18.9% fulfilled at least one of the “MCTD” criteria. The non-“MCTD” patients had other rheumatologic diseases (SLE 58%; RA 25%; UARD 15%; Sjogren’s 7%; primary Raynaud’s 7%; cutaneous lupus 6%; systemic sclerosis syndrome 2%) or, importantly, lacked any overt rheumatologic symptoms. It is also important to highlight that disease conversion (reviewed below) may also occur in anti-RNP-positive patients.

Several smaller studies have reported that “MCTD” patients have a high anti-RNP titre [1, 16, 19, 32]. However, Reiseter et al. compared the characteristics between “MCTD” stable patients and converters, in 147 patients, and reported higher median anti-RNP titles in disease converters—median (IQR): 27(5–66) in “MCTD” stable; 104(25–240) in disease converters. Furthermore, Ungerprast et al. also described high titres of anti-RNP antibodies in 46% of their 264 anti-RNP-positive population, but only 29% of the high anti-RNP pool (35/121) had “MCTD”.

Other antibodies (anti-dsDNA, Sm, Scl70, SSA/Ro, SSB/La, CCP, cardiolipin, β2GP, endothelial cell antibodies) have been reported in patients with MCTD with variable frequencies. Several studies have attempted to link different antibody profiles to clinical features and evolution to well-defined ARD. A more recent study [34] evaluated an association between HLA haplotype and evolution towards a well-established ARD. Gendi et al. [24] evaluated 39 “MCTD” patients after a 10-year follow-up time and found that 25 of those patients had evolved to another ARD, and that HLA DR4 was present in 10 of those 25 converters and 9 of the 14 non-converters. They also found an association between HLA haplotype and evolution towards a well-established ARD. A more recent study [34] evaluated 155 patients with a mean duration 11.6 years (SD 8.4) with the diagnosis of “MCTD”, comparing to 282 healthy controls, 96 SLE, 95 SSc and 84 PM patients. The presence of anti-U1RNP antibody in non-“MCTD” patients was not reported. HLA-DR4 was associated with “MCTD” (OR 2.8), unlike SLE that is described as being negatively associated with this HLA haplotype. HLA-B alleles were also evaluated and HLA-B8 was positively associated with “MCTD” (OR 2.0) SLE (OR:2.4) and PM (OR 3.3).

Evolution to well-established autoimmune rheumatic diseases

Disease stability is a core argument in favour of the existence of “MCTD” as an independent ARD. The aforementioned studies address this issue but report conflicting results (Table 2). Cappelli et al. noted a diagnostic conversion frequency of 42.1%, but this value was calculated considering that the “MCTD-stable” patients encompass those who also fulfil well-established ARD criteria. If the “MCTD-alone” patients are considered, the conversion frequency is 85.6% in this follow-up study over 7.9(±5.9) years.

In the Reiseter et al. study, the conversion frequency was 11.9% after a follow-up of 17 ± 9 years. As above, considering that conversion definition is not strict, it is not clear whether “MCTD-stable” patients also fulfilled other ARD criteria. It also considered remission on treatment (prednisolone ≤ 5 mg/day; azathioprine, methotrexate, mycophenolate mofetil) or not (treatment hydroxychloroquine, calcium channel blockers, intermittent non-steroid anti-inflammatory drugs were allowed). The absence of the anti-RNP antibody was considered a remission marker. Therefore, patients who once fitted the criteria for “MCTD” but no longer did, due to absent disease activity, were considered to have “MCTD”, regardless of their anti-RNP antibody status. Furthermore, the most common symptoms in patients with active “MCTD” disease were arthritis, rash and alopecia. Conversion to SLE occurred in 5 of 118 patients (4.3%) that developed high anti-dsDNA titres and low complement. RA was diagnosed in 4 of 118 patients (3.4%) with positive anti-CCP and bone erosions on X-ray, and they concluded that bone erosions are not common in “MCTD” and should raise suspicion about differentiation to other ARD. These results raise several questions, namely whether: anti-RNP antibodies were an intermittent finding and had no relation to therapy; therapy was concealing clinical manifestations that would otherwise occur and enable evolution into a well-defined ARD; if the “MCTD-stable” patients fulfilled other ARD criteria and, in fact, had an well-defined ARD.

Hajas et al. described an “no disease conversion” over a period of 13.1(±7.5) years. It is not clear which criteria were used to evaluate disease conversion. As described below, 78.2% patients were treated with high-dose steroids, 74.6% with cytotoxic agents and 15% with anti-TNF agents. In this cohort, 11 patients had renal disease with a biopsy showing thrombocytopenic thrombotic purpura/haemolytic-uremic syndrome (TTP/HUS) in 3 patients, ISN class II (5 patients) or class V glomerulonephritis (3 patients). Anti-dsDNA antibodies were present in 3.2% and anti-Sm antibodies in 6.7%, but complement levels were not measured. An association with anti-phospholipid syndrome (APS) was also described in 72 of 280 patients (25.7%), in contrast to previous reports (19,35) that
| Name of study | n   | Follow-up time—mean (SD) | Classification criteria at diagnosis | Treatment | Outcome |
|--------------|-----|--------------------------|-------------------------------------|-----------|---------|
|              |     |                          | Sharp [10]  Kasukawa [12]  Alarcón-Segovia [11]  Kahn [13] |           |         |
| Cappelli et al. [25] | 161 | 7.9 (5.9)                | 41.6%  75.2%  73.3                      | Not used  58%<sup>a</sup> immunosuppressant 82%<sup>b</sup> steroids 45% antimalarial drug | 57.9%<sup>c</sup> (14.4% MCTD alone; 40.5% MCTD + other ARD) 42.1% | Deaths in the MCTD group (n=161) 5/161 = 3.1% |
| Reiseter et al. [26] | 118 | 17 (9)                   | 96.6%  85.6%  91.6                      | Not used  Not reported | 88.1% | 11.9% | Loss of follow = 13 Deaths in the MCTD group (n=134) 16/134 = 11.9% |
| Hajas et al. [27] | 280 | 13.1 (7.5)               | Not used  Not used  100                   | Not used  78.2% high-dose steroid<sup>6</sup> 74.6% cytotoxic agent<sup>6</sup> 15% anti-TNF | 100% | 0 | Deaths in the MCTD group (n=280) 22/280 = 7.9% |
| Ungprasert et al. [4]<sup>f</sup> | 264 (50)<sup>g</sup> | 8.3 (3.4; 14.1)<sup>h</sup> | 28%  72%  72                  | Not used  Not reported | 90% | 10% | Deaths in the MCTD group (n=50) 5/50 = 10% |

<sup>a</sup>Cyclophosphamide, cyclosporine, mofetil mycophenolate, azathioprine, methotrexate and leflunomide  
<sup>b</sup>Dose not explicit  
<sup>c</sup>Percentages according to Kasukawa criteria set as it was considered the most accurate in this study  
<sup>d</sup>≥ 1 mg/kg/day methylprednisolone  
<sup>e</sup>Methotrexate, cyclophosphamide, azathioprine  
<sup>f</sup>Cohort study of anti-RNP-positive patients  
<sup>g</sup>264 RNP positive. 50 fulfilled MCTD criteria at follow-up initiation  
<sup>h</sup>Median; interquartile range
described patients with positive APS antibodies without clinical APS criteria. In contrast to Reiseter et al., erosive arthritis was diagnosed in 17.5% of patients, after 5 to 10 years of the “MCTD” diagnosis. An anti-CCP antibody was positive in 18.9% at the end of the follow-up. Analysing this study, although the data are scattered, it is debatable whether some of these “MCTD” patients would not have fulfilled other ARD criteria.

Ungprasert et al. reported a 10% conversion rates, but again no description of the criteria used to determine whether other ARD had developed, nor which treatment was given.

Treatment and prognosis

The treatment of “MCTD” is relatively little discussed. In Hajas et al., 219 of 280 (78.2%) patients were treated with high-dose steroid (≥ 1 mg/kg/day methylprednisolone), 209 (74.6%) with cytotoxic agent (methotrexate, cyclophosphamide, azathioprine) and 42 (15%) with anti-TNF. Cappelli et al. reported 58% patients treated with immunosuppressants (cyclophosphamide, cyclosporine, mofetil mycophenolate, azathioprine, methotrexate, leflunomide), 82% requiring glucocorticoids (no dose reported) and 45% of patients treated with antimarial drugs. Thus, in these studies, most patients needed immunosuppressive treatment. Treatment varied with organ evolvement, in accordance with current well-defined ARD guidelines.

Ungprasert et al. reported 10% deaths, but the overall mortality rate was not different from the general population. Reiseter et al. also reported 11.9% deaths in their group, although these patients had an older mean age and higher prevalence of pericarditis and ILD. Hajas et al. described 7.9% deaths in their study. The major cause of death was PAH, followed by cardiovascular events and TTP/HUS. Overall, the prognosis appears to be connected to the presence of pulmonary disease.

Diagnostic criteria and current guidelines

Overall, it is hard to escape the conclusion that there is no current evidence or agreement about the optimal criteria for diagnosis, follow-up or treatment strategies. It may be argued that larger studies are needed to allow these conclusions. It is evident that these patients might require careful periodic lung involvement evaluation.

Hajas et al. used one set of diagnostic criteria, whereas all the other studies used several different diagnostic criteria sets. No agreement on which one is the most sensitive criteria set was achieved, when comparing the studies analysed.

Undifferentiated autoimmune rheumatic disease overview

UARD is a term used to capture those patients with clinical features and antibodies compatible with an ARD, but who do not fulfil the criteria for any well-defined individual ARD. Currently, there are no globally accepted diagnostic criteria [35, 36]. Symptom frequency described in several cohort studies are scattered, as in “MCTD”, although most studies have 5-year follow-up time or less [36]. Arthritis frequency ranges from 15.2 to 33%, Raynaud’s phenomenon from 6.3 to 58.8%, malar rash 3% to 25.3% and photosensitivity 17 to 40.5% [36]. Pulmonary disease is not described as frequently as in the “MCTD” cohorts, but UARD cohorts have a shorter follow-up time, some of them are considerably larger, and pulmonary disease may not have been systematically sought. In contrast, Kinder et al. evaluated 280 patients with ILD, 53 (18.9%) of those patients had a well-defined ARD associated (only 1 patient had “MCTD”—0.4%) and 28 (10%) patients had UARD [37]. Similarly, Alhamad et al. reported a comparison of patients with idiopathic pulmonary fibrosis versus 67 patients with ARD-related ILD (ILD-ARD). Among these ILD-ARD patients, 33% were described as UARD and only 6% as “MCTD”. Thus, pulmonary disease in UARD may have a bigger incidence than that described in UARD cohorts. More studies are needed. Oesophageal hypomobility is rarely reported [38], and sometimes, only dysphagia is mentioned [39], with a range from 1 to 7.2%. Iudici et al. addressed the quality of life in 46 patients with UARD (follow-up 7.5 ± 5.5 years), among whom, gastrointestinal symptoms (dysphagia/heartburn and early satiety) were reported in 32.6% [40]. Anti-RNP antibodies are reported in the UCTD cohorts, with no consistent clinical significance [38, 39, 41, 42]. Evolution to well-established ARD ranged between 5 and 68%. Some studies describe a relation between evolution to well-established ARD with antibody association at presentation or new antibody appearance during follow-up [38, 39, 42]. As with “MCTD”, patients are treated similarly to those with the well-established ARD [38, 39, 41, 42].

Final discussion

Following the original claims about the existence of a new entity, “MCTD” rapidly became very popular. Perhaps this was because rheumatologists sought to “accentuate the positive”, when explaining to their patients that while
they had a disease of their immune system, its symptoms were relatively mild, the corticosteroid requirement was low, the symptoms annoying but not serious and, most importantly, prognosis was good. Sadly, it is very clear, from this and earlier reviews [7–9], that none of these beliefs really stands up to critical scrutiny and nor does the implication that high levels of antibodies to RNP must be present to fit any diagnostic criteria. The experience that we and many other groups have had is that there are many individuals with high levels of antibodies who do not have the “classical” symptomatology of the so-called MCTD, and likewise, there are patients with these symptoms who have either low titres or no evidence of anti-RNP antibodies. The original claim that there were no pulmonary or renal disease features in these patients is clearly incorrect, especially with regard to the former, and it is notable that pulmonary hypertension seems to be a relatively common cause of death in patients still diagnosed with “MCTD”. The requirement for corticosteroid, and other immunosuppressive drugs, which were said to be low/modest is also untrue.

Although no direct comparison has been made, reviewing the “MCTD” and UARD literature, there are no striking differences regarding clinical presentation, evolution, treatment, and prognosis. It would be interesting to compare all the undifferentiated patients (“MCTD” and UARD) anti-RNP positive and negative.

**Conclusion**

While we do not pretend that there are no patients who may have high levels of antibodies to RNP and whose clinical features fall within the “MCTD” description, many of these patients, as clearly indicated by long-term follow-up studies, “evolve” into other more specific ARDs. We take the view that the patients, whose clinical features remain stable, would best be described as having an undifferentiated ARD. The term MCTD seems to us thoroughly discredited and does not better define these patients.

Further and larger studies are still needed to assess the significance of anti-U1RNP antibodies in ARD. Further long-term cohort studies encompassing all undifferentiated patients are also needed to ascertain diagnostic criteria, optimal follow-up, treatment and prognosis.

**Compliance with ethical standards**

**Conflict of interest** The authors declare they have no conflict of interest.

**References**

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148–59.
2. Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore). 1980;59(4):239–48.
3. Carpintero MF, Martinez L, Fernandez I, et al. Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus. 2015;24(10):1057–66.
4. Ungprasert P, Crowson CS, Chowdhary VR, Erste FC, Modr KG, Matteson EL. Epidemiology of mixed connective tissue disease, 1985–2014: a population-based study. Arthritis Care Res. 2016;68(12):1843–8.
5. Kim P, Grossman JM. Treatment of mixed connective tissue disease. Rheum Dis Clin N Am. 2005;31(3):549–65.
6. Lundberg IE. The prognosis of mixed connective tissue disease. Rheum Dis Clin N Am. 2005;31(3):535–47.
7. Black C, Isenberg DA. Mixed connective tissue disease—Goodbye to all that. Rheumatology. 1992;31(10):695–700.
8. Swanton J, Isenberg D. Mixed connective tissue disease: still crazy after all these years. Rheum Dis Clin N Am. 2005;31(3):421–36.
9. Ciang NCO, Pereira N, Isenberg D. Mixed connective tissue disease-enigma variations? Rheumatol Oxf Engl. 2017;56(3):326–33.
10. Sharp GC. Diagnostic criteria for classification of MCTD. Amsterdam: Elsevier; 1987. p. 23–32.
11. Alarcón-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. Amsterdam: Elsevier; 1987. p. 33–40.
12. Kasukawa R, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 41–7.
13. Kahn MF, Appeboom T. Syndrome de Sharp. Mal Syst Vol 3 Paris Flammarion 1991; 545–56.
14. Entezami P, Fox DA, Clapham PJ, Chung KC. Historical perspective on the etiology of rheumatoid arthritis. Hand Clin. 2011;27(1):1–10.
15. Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM Int J Med. 2010;103(3):139–46.
16. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin N Am. 2005;31(3):411–20.
17. Martínez-Barrio J, Valor L, López-Longo FJ. Facts and controversies in mixed connective tissue disease. Med Clin (Barc). 2018;150(1):26–32.
18. Farhey Y. Mixed connective tissue disease (MCTD) — a coming of age. Curr Rheumatol Rev. 2012;8(1):20–9.
19. Aringer M, Smolen JS. Mixed connective tissue disease: what is behind the curtain? Best Pract Res Clin Rheumatol. 2007;21(6):1037–49.
20. Black CM, Maddison PJ, Welsh KI, Bernstein R, Woodrow JC, Pereira RS. HLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis Rheumatol. 1988;31(1):131–4.
21. Hoffman RW, Rettenmaier LJ, Takeda Y, et al. Human autoantibodies against the 70-kd polypeptide of u1 small nuclear rnp are associated with HLA-DR4 among connective tissue disease patients. Arthritis Rheumatol. 1990;33(5):666–73.
22. Ruuska P, Hämeenkorpi R, Forsberg S, et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann Rheum Dis. 1992;51(1):52–5.
23. Genth E, Zarnowski H, Mierau R, Hartl PW, HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Ann Rheum Dis. 1987;46(3):189–96.
24. Gendi NS, Welsh KI, Van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic follow-up of 46 patients. Arthritis Rheum. 1995;38(2):259–66.
25. Cappelli S, Bellando Randone S, Martinović D, et al. ‘To be or not to be’, ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012;41(4):589–98.
26. Reiseter S, Gunnarsson R, Corander J, et al. Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study. Arthritis Res Ther. 2017;19(1):284.
27. Hajas A, Szodoray P, Nakken B, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol. 2013;40(7):1134–42.
28. Szodoray P, Hajas A, Kardos L, et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus. 2012;21(13):1412–22.
29. Frandsen PB, Kriegaum NJ, Ullman S, Høier-Madsen M, Wiik A, Halberg P. Follow-up of 151 patients with high-titer U1RNP antibodies. Clin Rheumatol. 1996;15(3):254–60.
30. Gunnarsson R, Aaløkken TM, Molberg Ø, et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012;71(12):1966–72.
31. Kinder BW, Shariat C, Collard HR, et al. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010;188(2):143–9.
32. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheumatol. 1999;42(5):899–909.
33. Isenberg D. Thirty years, five hundred patients: some lessons learned from running a lupus clinic. Lupus. 2010;19(6):667–74.
34. Flåm ST, Gunnarsson R, Garen T, Norwegian MCTD Study Group, Lie BA, Molberg Ø. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatol Oxf Engl. 2015;54(3):528–35.
35. Hoffman RW, Greidelberg EL. Mixed connective tissue disease. Curr Opin Rheumatol. 2000;12(5):386–90.
36. Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48–49:50–2.
37. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2007;176(7):691–7.
38. Danieli MG, Praticelli P, Fraceschini F, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue disease. Clin Exp Rheumatol. 1999;17(5):585–91.
39. Vaz CC, Couto M, Medeiros D, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009;28(8):915–21.
40. Iudici M, Irace R, Riccardi A, Cuomo G, Vettori S, Valentini G. Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. Patient Relat Outcome Meas. 2017;2(8):7–13.
41. Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002;29(11):2345–9.
42. Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21(3):313–20.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.